The in vitro interaction of RA-233 and several interferons on human cell lines.
The antiproliferative effects of six different human interferons were examined in two human cell lines: HM7 (human melanoma cell line) and MDA-MB-231 (human breast carcinoma cell line). A dose-response curve was developed for each interferon in which the maximum dose applied gave at least 30% growth inhibition of control values after 96-128 hours of continuous exposure. An amount of RA-233 which caused 25% growth inhibition (0.05 mg for both HM7 and MDA-MB-231 cell lines) was added to the cultures with various doses of each interferon. The inhibitory effects of RA-233 and each interferon were additive at low concentrations. In no case was a synergistic effect observed. Unlike with human fibroblast interferon, we could not show a synergistic inhibitory effect between RA 233 and any of the six different interferons on these two human epithelial tumor cell lines.
D001943:Breast Neoplasms / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004357:Drug Synergism; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D008545:Melanoma / Q000473:pathology*; D009012:Mopidamol / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
D007370:Interferon Type I; D011743:Pyrimidines; D009012:Mopidamol; D007371:Interferon-gamma